Oligoclonal antibodies to target the ErbB family.
BACKGROUND
Use of mAbs to inhibit signaling through the ErbB receptor tyrosine kinase family has proven to be an effective strategy for treating ErbB-driven cancers. Advances in the field of antibody engineering and manufacturing now allow us to more effectively mimic the natural immune response by generating oligoclonal mixtures of antibodies against desired targets of interest.


METHODS
In this review, we examine the literature describing the development of oligoclonal mixtures of antibodies against ErbB family members and the impact of those mixtures on preclinical and clinical efficacy.


CONCLUSIONS
Oligoclonal antibodies, facilitated by the improved antibody engineering and manufacturing techniques, hold the promise of improving patient outcomes. Through the use of empirical methods, oligoclonal mixtures with enhanced capacity to block signaling through ErbB family members can be identified. The intrinsic mechanisms associated with each of the component mAbs provide an opportunity to block signaling via multiple mechanisms of action. In addition, combinations of antibodies targeting multiple ErbB family members provide the capacity to down-regulate signaling through multiple components of this critical pathway.
Fox Chase Cancer Center, Molecular Therapeutics Program , Philadelphia, PA 19111 , USA matthew.robinson@fccc.edu.
Jimson W
JW
D'Souza
Matthew K
MK
Robinson
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins; D066246:ErbB Receptors
ErbB; antibody; clinical; oligoclonal; preclinical